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Abstract 
Background: Anaplasma phagocytophilum (formerly Ehrlichia phagocytophila) is an obligate intracellular bacterium 
causing the disease tick‑borne fever (TBF) in domestic ruminants. An effective vaccine against the infection has been 
demanded for livestock by sheep farmers and veterinary practitioners for years.
Findings: In the present study, we immunized lambs with an inactivated suspension of 1 × 108 killed A. phagocyt-
ophilum organisms mixed with adjuvant (Montanide ISA 61VG; Seppic). Twelve 9‑months‑old lambs of the Norwegian 
White Sheep breed were used. A full two‑dose series of immunization was given subcutaneously to six lambs with 
a 4 week interval between injections. One month after the last immunization, all lambs were challenged with the 
homologous viable variant of A. phagocytophilum. After challenge, all lambs showed clinical responses for several 
days, although the immunized lambs reacted with an anamnestic response, i.e. significant reduction in infection rate 
and a significantly higher antibody titer.
Conclusion: Immunization with inactivated A. phagocytophilum did not protect lambs TBF.
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Findings
Tick-borne fever (TBF) caused by the bacterium Ana-
plasma phagocytophilum (formerly Ehrlichia phagocytoph-
ila) is an endemic disease of sheep in tick (Ixodes ricinus) 
infested areas of Norway [1]. TBF has for decades been 
one of the main scourges for the sheep industry in the 
coastal areas of Norway. An effective vaccine against the 
infection has been demanded by sheep farmers and vet-
erinary practitioners in Norway for years. However, there 
are currently no vaccines available against TBF. In endemic 
areas, prophylactic use of long-acting tetracycline, regular 
dipping or pour-on treatment with pyrethroids are used 
extensively [2]. However, there is a growing concern about 
the environmental safety and human health, increasing 
resistance in bacteria and their vectors related to antibiot-
ics and chemical controls of ticks [3].
In the present study we investigated if an inactivated 
crude antigen based on inactivated bacteria from buffy 
coat extracts could protect lambs upon challenge with 
live A. phagocytophilum.
Twelve unexposed 9-months-old lambs of the Norwe-
gian White Sheep breed were used. All lambs belonged 
to the experimental sheep flock at the Department of 
Production Animal Clinical Sciences and were housed 
indoors during the trial. Two groups of lambs with 
mixed gender and equal distribution of mean live weight 
were established. The experimental study was ethically 
approved by the National Animal Research Authority 
(Norway).
The strain of A. phagocytophilum used originated from 
an infected lamb in a Norwegian sheep flock known to 
have problems with TBF. Based on partial sequenc-
ing of the 16S rRNA gene, the variant of A. phagocyt-
ophilum was identical to GenBank accession number 
M73220. This variant has previously been evaluated in 
several infection studies [4, 5], and infected heparinised 
blood was stored at −70°C with 10% dimethyl sulphox-
ide (DMSO). The batch of inoculum was used for antigen 
preparation and in the later infection challenges.
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In order to obtain a sufficient amount of bacterial 
inoculum, one unexposed lamb was infected intrave-
nously with 2 ml of a heparinized DMSO-stabilate of A. 
phagocytophilum. On the second day of fever (day 5 after 
inoculation), 300  ml Na-citrated blood was collected 
from this lamb and the buffy coat was obtained at 4–6°C, 
by centrifugation in a swing-bout bucket rotor (Heraeus 
Multifuge 3S-R, Termo Sci. Germany) at 2,500×g for 
30 min. The isolated buffy coat was washed three times in 
1× PBS at 1,500×g for 20 min, and re-suspended in PBS 
after the last centrifugation. Quantification of the bacte-
rial content in the buffy coat was determined by qPCR 
[6]. The buffy coat was frozen in 10 ml aliquots at −70°C 
for further analysis.
For antigen preparation, 10  ml frozen buffy coat con-
taining approximately 8 × 108 copies of A. phagocytophi-
lum per ml was used. The material was inactivated using 
0.3% formaldehyde [7] for 48  h at room temperature. 
Thereafter, the material was tested for lack of infectivity 
by intravenous inoculation into two naive lambs (data not 
shown).
The final preparation was made by mixing 1  ml inac-
tivated buffy coat and 1 ml adjuvant (Montanide ISA 61 
VG, Seppic). The antigen solution and the mineral oil 
adjuvant were mixed to water in oil emulsion using two 
syringes connected by a three way valve [7]. The final 
antigen dose contained approximately 1  ×  108 inacti-
vated A. phagocytophilum and was used immediately 
after preparation.
Six lambs were immunized subcutaneously twice 
(one month apart) with the inactivated crude antigens. 
One month after the last immunization, all lambs were 
infected intravenously with 2 ml of the homologous via-
ble batch of A. phagocytophilum with an approximate 
infection dose equal to 0.5  ×  106 infected neutrophils 
per ml. A similar dose has earlier been used in other A. 
phagocytophilum infection studies [1, 4].
The lambs were clinically observed daily and the rec-
tal temperature was measured, starting on the first day of 
immunization [5]. Blood samples (EDTA) were collected 
every third day for the first 14 days after each immuniza-
tion and then daily during the fever period following the 
inoculation of infective blood. After the fever had sub-
sided, blood samples were collected on a weekly basis. 
From these EDTA-blood samples haematological values 
including total and differential leucocyte counts were 
determined electronically (Technicon H1®, Miles Inc., 
USA) and blood smears were prepared and stained with 
May-Grünwald Giemsa [5].
In order to detect A. phagocytophilum infection EDTA-
blood samples were also analysed for Anaplasma-DNA 
by qPCR [6]. In addition, sera were collected every sec-
ond week post each immunization and after challenge on 
days 0, 7, 14, 21, 28, 42, and 63. Sera were analyzed using 
an indirect immunofluorescence antibody assay (IFA) to 
determine the antibody titers to an equine variant of A. 
phagocytophilum (formerly Ehrlichia equi) [8].
Statistical calculations were done using Statistix, ver-
sion 4.0 (Analytical Software), and a two-sample t test 
was used to compare clinical, haematological and sero-
logical variables. A P value of <0.05 was considered 
significant.
No clinical signs or haematological changes were 
observed after immunization. However, all immunized 
lambs reacted with a firm palpable subcutaneous nod-
ule without abscess formation at the site of inoculation, 
starting 3–4 days after each immunization which disap-
peared about 4 weeks post immunization.
After challenge, all lambs reacted with fever, bacterae-
mia, neutropenia and an antibody response typical of an 
A. phagocytophilum infection [4]. Although the result 
indicates a difference in the clinical and haematological 
variables, no significant differences were obtained (data 
not shown). However, there was a significant difference 
(P  <  0.01) in level of bacteraemia (from days 4–9) and 
the antibody responses between immunized and con-
trol groups (Figs. 1, 2). After challenge, relapses of fever 
for 1–3 days occurred in two (33%) and five (83%) of the 
immunized and control lambs, respectively.
In the present study, no serologic response was 
observed after immunization. Lack of seroconversion 
observed in the immunized lambs could be due to low 
immunogenicity to the antigens used. However, the pre-
sent serological test has earlier been used successfully 
when lambs were infected with the currently described 
variant of A. phagocytophilum [4]. Lack of detectable 
immune response could also be due to a low dose of anti-
gen, masking of epitopes by formaldehyde treatment or 
the adjuvant used. Montanide ISA and formaldehyde 
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Fig. 1 Antibody titers in A. phagocytophilum‑immunized (days 0 and 
28) (white arrow) and control lambs. All lambs were challenged with 
live bacteria on day 56 (black arrow). A titer below 1.6 (<1/40) was 
considered negative.
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have earlier been included in vaccine preparations [7, 9], 
and a similar dose of antigen was used in a vaccination 
study with the related organism Ehrlichia ruminantium 
[10].
After challenge, there were no significant differences in 
temperature reaction or the differential leucocyte counts 
between the two groups of lambs, although significant 
differences (P  <  0.01) were observed in infection levels 
and antibody responses. The increased number of fever 
relapses in the unimmunized lambs, indicates a more 
solid immunity to A. phagocytophilum after immuniza-
tion [11]. These results indicate an anamnestic response, 
although too small to give protective immunity.
Immunity after experimental infection with a live vari-
ant of A. phagocytophilum varies from weeks to years [1]. 
A. phagocytophilum are obligate intracellular pathogens 
and cellular immunity is in general necessary for an effec-
tive immunity against such organisms [11]. However, 
antibodies to rickettsial infections have been shown to 
block the initial adhesion and penetration of the bacte-
rium, enhance phagosome-lysosome fusion and phago-
cytosis followed by destruction of the organisms [12, 13].
An earlier observation indicates that specific antibod-
ies could induce protection from Anaplasma infection. 
In one trial, mice were either vaccinated with a lysate of 
human variant of A. phagocytophilum (HGA-agent) or 
were given HGA-antisera directly from vaccinated mice. 
After challenge with the same variant, these mice were 
partially protected, indicating that antibodies are suffi-
cient to protect substantially, but not fully against infec-
tion [14].
Crude preparation of the bacteria may expose mainly 
dominant antigens giving poor protection against disease 
due to irrelevant antigens derived either from the agent 
itself or from material used to produce it [15], although 
no detectable serological response was obtained after a 
similar immunization trial in lambs, using a purified cell-
cultured variant of A. phagocytophilum (Stuen, unpub-
lished results).
In order to develop a successful vaccine, the challenge 
is to choose shared or subdominant antigens that are 
conserved amongst all strains of A. phagocytophilum and 
to produce these in sufficient quantity [16–18]. Genome 
sequencing of multiple strains [19] may be required to 
identify conserved antigens. Further research to develop 
sub-unitvaccines or live vaccine candidates should there-
fore focus on promoting the expression of sub-dominant 
surface proteins of A. phagocytophilum, as described 
in recent studies on the related organism A. marginale 
[20–22].
In conclusion, immunization with antigens based on 
the whole bacterium did not protect lambs from an A. 
phagocytophilum infection. After challenge, all lambs 
showed clinical responses for several days, although 
the immunized lambs had reduced levels of infection. 
Improved antigens are necessary in order to obtain pro-
tection from bacteraemia and clinical manifestation of 
tick-borne fever.
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